A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL.

Trial Profile

A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Retapamulin (Primary)
  • Indications Bacterial infections; Wound infections
  • Focus Therapeutic Use
  • Acronyms SCRAPE
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Mar 2013 New source identified and integrated (Clinical Trials Registry - India, CTRI2009-091-000023).
    • 23 Dec 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 23 Dec 2009 Actual patient number (508) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top